WASHINGTON - Pfizer Inc. said Wednesday that a third shot of its coronavirus vaccine could offer sufficient protection against the new Omicron variant, while the two-dose regimen may be less effective, citing the results of an initial laboratory study.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
